BC Week In Review | Aug 3, 2015
Clinical News

BioPlex 2200 HIV Ag-Ab regulatory update

FDA approved a PMA from Bio-Rad for its BioPlex 2200 HIV Ag-Ab assay, which detects HIV antigens and antibodies and differentiates between HIV-1 and HIV-2. The HIV Ag-Ab kit assay runs on Bio-Rad’s BioPlex 2200...
BC Week In Review | Jun 23, 2014
Company News

Bio-Rad Laboratories Inc sales and marketing update

Bio-Rad launched outside of the U.S. its BioPlex 2200 HIV Ag-Ab kit, which detects HIV antigens and antibodies and differentiates between HIV-1 and HIV-2. The kit runs on Bio-Rad’s BioPlex 2200 system - an immunoassay platform...
BC Week In Review | Oct 18, 2010
Clinical News

BioPlex 2200 Anti-CCP test regulatory update

FDA granted 510(k) clearance to Bio-Rad's BioPlex 2200 Anti-CCP test for the early detection of rheumatoid arthritis. Bio-Rad said it also launched the test in the U.S. and already markets it outside the U.S. The...
BC Week In Review | Nov 19, 2007
Company News

Bio-Rad Laboratories sales and marketing update

BIO launched a syphilis kit for use on its BioPlex 2200 system , a multiplexing technology platform to analyze disease markers from a single patient sample. The IgG kit detects three bacteria that cause syphilis. BIO...
BC Week In Review | Apr 9, 2007
Company News

Bio-Rad Laboratories sales and marketing update

BIO launched two Epstein Barr virus (EBV) kits for use on its BioPlex 2200 system , a multi-plexing technology platform to analyze disease markers from a single patient sample. The IgG kit includes assays for EBV...
BC Week In Review | Jan 15, 2007
Company News

Axis-Shield, Bio-Rad Laboratories deal

BIO received a non-exclusive license to incorporate ASD's test for detecting rheumatoid arthritis (RA) on BIO's automated analyzers, including the BioPlex 2200 system . ASD's ELISA-based assay detects antibodies against cyclic citrullinated peptides, which are specific...
BC Week In Review | Jan 10, 2005
Clinical News

BioPlex 2200 system regulatory update

FDA granted marketing clearance for BIO's BioPlex 2200 system, an immunoassay platform with multiplexing technology to analyze multiple disease states from single patient samples. The system will initially include a panel of assays targeting autoimmune...
Items per page:
1 - 7 of 7